9258 Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

9258 Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,680	Closed	-$201K	–	329
2022 Q4	$201K	Buy	+1,680	New	+$197K	0.04%	311
2021 Q4	–	Sell	-3,702	Closed	-$355K	–	375
2021 Q3	$355K	Hold	3,702	–	–	0.09%	226
2021 Q2	$360K	Buy	3,702 +19	+0.5%	+$1.82K	0.1%	221
2021 Q1	$358K	Sell	3,683 -71	-2%	-$7.45K	0.11%	205
2020 Q4	$360K	Buy	3,754 +365	+11%	+$35.3K	0.12%	194
2020 Q3	$334K	Buy	3,389 +91	+3%	+$10.5K	0.13%	187
2020 Q2	$402K	Buy	3,298 +10	+0.3%	+$1.1K	0.16%	156
2020 Q1	$334K	Buy	3,288 +156	+5%	+$15.3K	0.15%	171
2019 Q4	$337K	Buy	+3,132	New	+$328K	0.12%	204

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

9258 Wealth Management's NBIX Position: Q1 2023 in Review

9258 Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 1,680 shares — an estimated $201K sold.

9258 Wealth Management first reported a position in NBIX in Q4 2019 and held it in 9 quarters. The position peaked at $402K in Q2 2020. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

9258 Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
9258 Wealth Management sold 1,680 Neurocrine Biosciences shares in Q1 2023, an estimated $201K.
9258 Wealth Management first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 9 quarters.
9258 Wealth Management's Neurocrine Biosciences position peaked at $402K in Q2 2020.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on 9258 Wealth Management's 13F filing for Q1 2023, filed 3 May 2023.